Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer

Inclusion Criteria: * Histologic or cytologic history diagnosis of primary ovarian, primary peritoneal or tubal carcinoma * Asymptomatic from ovarian cancer * Evidence of recurrent ovarian, peritoneal or tubal carcinoma * Tumor sample must be positive for ER and/or PR * 18 years of age or older * ECOG performance status of less than or equal to 1 * Must be able to tolerate oral intake Exclusion Criteria: * Known hypersensitivity to Iressa or any of the excipients of this product * Other coexisting malignancies or malignancies diagnosed within the last 5 years * Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital or St. John's wort * Treatment with a non-approved or investigational drug within 30 days * Any unresolved chronic toxicity greater than CTC grad 2 from previous anticancer therapy (except alopecia) * Incomplete healing from previous oncologic or other major surgery * Serum creatinine level greater than CTC grade 2 * Pregnant or breast feeding * Severe uncontrolled systemic disease * Significant clinical disorder or laboratory finding that makes it potentially unsafe for the subject to participate * Patients currently receiving other investigational antineoplastic agents, on systemic chemotherapy or under radiation therapy treatment * Patients previously treated with anastrozole or other aromatase inhibitor * Unable to tolerate oral medications * Clinical and/or radiographic evidence of current or impending bowel obstruction